A 5-Day genetic test could slash time to transplant for children with rare immune disease
NCT ID NCT07741747
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial tests whether a new ultra-rapid genetic test, using third-generation sequencing, can diagnose familial lymphohistiocytosis (FHL) in children within 5 days instead of the usual 6-8 weeks. FHL is a rare, life-threatening genetic condition where the immune system attacks the body, and early diagnosis is critical for starting treatment and a bone marrow transplant. The study will measure how this faster diagnosis affects the time to transplant and overall outcomes in 240 children under 18 with suspected FHL.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Third-generation sequencing (a rapid genetic test on a blood sample)
- What this could lead to
- If successful, this could dramatically shorten the time to diagnosis and bone marrow transplant for children with familial lymphohistiocytosis, potentially improving survival.
- What could go wrong
- The trial is early and the test's speed may not translate into better outcomes. The technology must prove reliable in real-world settings, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHÉDIAK-HIGASHI SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique - Hôpitaux de Marseille
Marseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.